Epigenomics AG
EPGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $339 | $485 | $6,203 |
| % Growth | -100% | -30.1% | -92.2% | – |
| Cost of Goods Sold | $12 | $57 | $120 | $136 |
| Gross Profit | -$12 | $282 | $365 | $6,067 |
| % Margin | – | 83.2% | 75.3% | 97.8% |
| R&D Expenses | $0 | $0 | $6,191 | $3,111 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,228 | $4,215 | $4,296 | $4,437 |
| Sales & Mktg Exp. | $0 | $0 | $4,296 | $4,437 |
| Other Operating Expenses | -$62 | $566 | $1,929 | $873 |
| Operating Expenses | $1,166 | $4,781 | $12,416 | $8,421 |
| Operating Income | -$1,178 | -$4,177 | -$12,051 | -$2,354 |
| % Margin | – | -1,231.2% | -2,484.7% | -37.9% |
| Other Income/Exp. Net | -$2,292 | -$287 | -$50 | -$56 |
| Pre-Tax Income | -$3,470 | -$4,464 | -$12,101 | -$2,410 |
| Tax Expense | $0 | $0 | -$77 | $18 |
| Net Income | -$3,470 | -$4,464 | -$12,024 | -$2,428 |
| % Margin | – | -1,315.8% | -2,479.2% | -39.1% |
| EPS | -3.96 | -5.23 | -14.78 | -4.33 |
| % Growth | 24.3% | 64.6% | -241.3% | – |
| EPS Diluted | -3.96 | -5.23 | -14.78 | -4.33 |
| Weighted Avg Shares Out | 877 | 853 | 813 | 560 |
| Weighted Avg Shares Out Dil | 877 | 853 | 813 | 560 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38 | $35 | $99 | $12 |
| Interest Expense | $0 | $0 | $130 | $52 |
| Depreciation & Amortization | $12 | $563 | $749 | $419 |
| EBITDA | -$3,458 | -$3,614 | -$11,222 | -$1,939 |
| % Margin | – | -1,065.2% | -2,313.8% | -31.3% |